Categories

Sign Up to Receive the Latest Trading Tips and News from Prosper



    February 15, 2019

    AcelRx Is Strong!

    AcelRx Pharmaceuticals (ACRX) shares rose strongly in trading today. The company received initial coverage from Credit Suisse, with an outperform rating and $7 price target. ACRX recently received FDA approval in late 2018 for its powerful opioid DSUVIA. The company insists that it will tightly regulate the distribution and dosage so as to avoid patients […]

    Read Article
    February 14, 2019

    Guardant Health Has A Couple Secret Admirers

    Guardant Health Inc. (Ticker: GH) shares were up strongly starting at the middle of the session. The rise appears to be due to the disclosure of passive stakes in the company by at least two funds. Shares moved as high as $48.46 as of the time this content was created, a gain of nearly 12%. […]

    Read Article
    February 12, 2019

    Axovant Sciences…So You Are Saying There’s A Chance

    Axovant Sciences, LTD (AXON) shares had a brief spike in trading today, but gradually slid back to negative territory for the session. The company’s shares have been under consistent negative pressure since the second half of 2017, primarily due to persistent failures of the gene therapy treatments the company has researched. While the market is […]

    Read Article
    February 11, 2019

    Take A Seat With Our Mike Patton

    Here’s a sneak peek of one of the industry’s most reputable, hands-on trading programs with Mike Patton. Grab a free day pass to one of our live signal trading rooms today>>http://bit.ly/fb-free-pass  

    Read Article
    February 11, 2019

    Not Great News For Vanda

    Vanda Pharmaceuticals (VNDA) shares moved lower today after a negative report from market research firm Aurelius Value. Aurelius disclosed that it holds a short position in the stock, and alleges that VNDA’s CEO has engaged in fraudulent schemes along with his company as a whole. Here’s a recap.

    Read Article
    February 8, 2019

    Learn About One Of the Market’s Hottest Markets With Mike Patton

    Here’s a sneak peek of one of the industry’s most reputable, hands-on trading programs with Mike Patton. Grab a free day pass to one of our live signal trading rooms today>>http://bit.ly/fb-free-pass  

    Read Article
    February 8, 2019

    Muddy Waters Certainly Muddied the Waters For Inogen

    Inogen Inc (INGN) shares were pressed lower in trading today after a negative report by short-seller Muddy Waters was published earlier today. The report alleged that the company’s management has inflated projections of future sales growth to its investors, thus pushing the stock price much higher than would be reasonable. The stock bounced back after […]

    Read Article
    February 7, 2019

    Look Out Below For Sangamo Therapeutics

    Sangamo Therapeutics (SGMO) shares slumped over -30% lower due to a failed Phase 1/2 study. The company reported its SB-318 genome editing product did not appear to show any clinical benefits. The company does have an extensive pipeline of treatments in clinical trials, as well as partnerships with major companies such as Pfizer. However, this […]

    Read Article
    February 5, 2019

    Evolus, Part II

    Evolus, Inc. (EOLS) is up again today following FDA approval of its first product, Jeuveau, on Friday. The stock was up over 25% at the time this content was recorded. Part of this rally is likely due to the fact that the stock had a large percentage of short positions. In fact, nearly a fifth […]

    Read Article
    February 4, 2019

    Did Evolus Just Find the Fountain Of Youth?

    Evolus Inc (EOLS) shares are up sharply today after the company gained FDA approval for their flagship product, Jeuveau, a cosmetic injection used to reduce the appearance of wrinkles on the face. This means Jeuveau is a direct competitor to Botox, which of course is a big seller for its parent company, Allergan. Here’s a […]

    Read Article